Group 1 - The company, Gushengtang (02273), announced a share buyback plan on December 11, 2025, involving an expenditure of HKD 12.1799 million [1] - The company will repurchase a total of 435,100 shares at a price range of HKD 27.62 to HKD 28.44 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on December 10, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Companies with Significant Buybacks - Tencent Holdings (00700) repurchased 1.06 million shares for a total of 636 million, representing 0.961% of its total share capital [2] - Xiaomi Group-W (01810) repurchased 2.4 million shares for 101 million, accounting for 0.400% of its total share capital [2] - China Feihe (06186) repurchased 5.47 million shares for 22.94 million, which is 2.521% of its total share capital [2] Group 2: Other Notable Buybacks - Geely Automobile (00175) repurchased 1.54 million shares for 27.14 million, representing only 0.047% of its total share capital [2] - Kweichow Moutai (600519) repurchased 204,000 shares for 8.82 million, which is 0.180% of its total share capital [2] - Vitasoy International (00345) repurchased 404,000 shares for 2.67 million, accounting for 2.180% of its total share capital [2] Group 3: Companies with Lower Buyback Amounts - 康臣药业 (01681) repurchased 354,000 shares for 5.28 million, which is 15.048% of its total share capital [2] - 瑞声科技 (02018) repurchased 150,000 shares for 5.76 million, representing 0.492% of its total share capital [2] - 周黑鸭 (01458) repurchased 160,500 shares for 2.68 million, which is 1.407% of its total share capital [3]

Group 1 - The core viewpoint of the article highlights the significant share buybacks and insider buying by the company, indicating strong confidence in its future prospects [1][2][3] Group 2 - The company has repurchased 6.12% of its total share capital this year, ranking fifth among all Hong Kong Stock Connect stocks [1] - From December 2 to 9, the company repurchased a total of 164,510 shares for a total amount of 46.97 million HKD, bringing the total number of shares repurchased this year to 1,434,290 shares for a total of 434 million HKD [2] - The founder and major shareholder, Tu Zhiliang, has also increased his stake by purchasing 476,000 shares for 14.27 million HKD from November 17 to 19, with total purchases this year exceeding 2.28 million HKD [3] Group 3 - The company has announced plans to maintain a dividend payout ratio of around 50% for the year 2025 and aims to distribute 50% of its profits as dividends annually over the next three years [4] - A new share buyback authorization of up to 300 million HKD (approximately 276 million RMB) has been granted, which, if fully utilized, could lead to a total shareholder return rate exceeding 10% by 2025 [4] Group 4 - In the first half of 2025, the company achieved a revenue of 1.495 billion RMB, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 152 million RMB, with a growth of 41.9% [5]

Group 1 - The company, Guoshengtang (02273.HK), has actively conducted share buybacks, repurchasing a total of 1.6451 million shares for a total amount of 46.9702 million HKD from December 2 to 9, 2023. Year-to-date, the company has completed 74 buybacks, totaling 14.3429 million shares and 434 million HKD in total buyback amount [1][3] - Guoshengtang's share buybacks represent 6.12% of its total share capital, ranking fifth among all Hong Kong Stock Connect stocks [1] - The founder and major shareholder, Tu Zhiliang, has also increased his stake in the company, acquiring 476,000 shares for a total of 14.273 million HKD from November 17 to 19, 2023. Year-to-date, he has purchased 786,000 shares for over 22.83 million HKD [3] Group 2 - The company has announced a significant increase in cash dividends, with management indicating a dividend payout ratio of around 50% for the full year of 2025 and plans to distribute 50% of annual profits as dividends over the next three years [3] - Guoshengtang has received a new share buyback authorization of up to 300 million HKD (approximately 27.6 million RMB). If fully utilized, combined with existing buybacks and a 50% dividend payout expectation, the total shareholder return is projected to exceed 10% by 2025 [3] - Guoshengtang is a leading Chinese medicine healthcare chain, operating over 80 offline clinics across 20 cities and an online service network covering over 340 cities in China. The company has more than 40,000 licensed practitioners, including seven renowned Chinese medicine masters, and has served over 20 million customers [4] Group 3 - In the first half of 2025, Guoshengtang achieved a revenue of 1.495 billion RMB, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 152 million RMB, reflecting a year-on-year increase of 41.9%. The net cash flow from operating activities was 296 million RMB, indicating stable growth in revenue and profit [4]

智通财经APP讯，固生堂(02273)发布公告，于2025年12月10日该公司斥资426.29万港元回购15.02万股， 回购价格为每股28.2-28.5港元。 ...

Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback on December 10, spending HKD 4.263 million to repurchase 150,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括 ...

Core Insights - The integration of technology and traditional Chinese medicine (TCM) is gaining momentum, with significant developments in AI applications within the industry [1][2] - Guoshengtang is positioning itself as a leader in TCM modernization and internationalization, aiming to enhance the quality and accessibility of TCM resources [1][3] Group 1: AI and Technology Integration - Guoshengtang has established strategic partnerships with top research teams to develop TCM-specific AI models, marking a shift from exploration to large-scale application [2][3] - The AI platform, "Guoyi AI Avatar," has achieved an expert simulation consistency of over 86%, enhancing the efficiency of online consultations and addressing the uneven distribution of quality medical resources [3][4] - The company has been building a digital infrastructure since 2019, accumulating extensive clinical data to support its AI initiatives [2][3] Group 2: Clinical Research and Evidence-Based Medicine - The launch of the "Xunyan Zhizhi" clinical research integration platform aims to address the challenges of evidence-based evaluation in TCM, utilizing AI to create a comprehensive innovation system [6][7] - This platform will facilitate the collection of accurate clinical data, enabling objective assessments of TCM efficacy and promoting a shift from experience-based to evidence-based medicine [6][7] Group 3: Global Expansion and Market Strategy - Guoshengtang is expanding its global footprint through a "merger + cooperation + self-built" strategy, with plans to acquire 14 clinics in Singapore and establish a joint venture with a digital healthcare platform [9][10] - The company has formed strategic partnerships with various platforms to enhance its service accessibility and user engagement, significantly increasing its customer acquisition rates [8][9] - By 2026, Guoshengtang plans to enter markets in Hong Kong and Malaysia, followed by expansion into Europe and the United States [1][9]

固生堂回购明细 | 日期 | 回购股数 | 回购最高价 | 回购最低价 | 回购金额 | | --- | --- | --- | --- | --- | | | （万股） | （港元） | （港元） | （万港元） | | 2025.12.09 | 34.01 | 28.400 | 28.020 | 959.73 | | 2025.12.08 | 22.06 | 28.480 | 27.860 | 622.16 | | 2025.12.05 | 18.60 | 28.460 | 28.460 | 529.36 | | 2025.12.04 | 20.00 | 28.680 | 28.420 | 571.93 | | 2025.12.03 | 32.00 | 28.980 | 28.520 | 919.33 | | 2025.12.02 | 37.84 | 29.380 | 28.700 | 1094.52 | | 2025.11.28 | 28.76 | 30.000 | 29.620 | 858.54 | | 2025.11.27 | 30.91 | 29.920 | 29.440 | 920.00 | | ...